Company profile for Alcyone Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are mission-driven to overcome the challenges in CNS therapy development through applying precision CNS delivery & dosing technologies to novel gene therapy technologies with a team of gene therapy and industry leaders.Our team holds deep scientific expertise and a passion to meaningfully change the lives of patients. Our number one priority is improving patient outcomes, and we are steadfast in our collaboration, innovatio...
We are mission-driven to overcome the challenges in CNS therapy development through applying precision CNS delivery & dosing technologies to novel gene therapy technologies with a team of gene therapy and industry leaders.Our team holds deep scientific expertise and a passion to meaningfully change the lives of patients. Our number one priority is improving patient outcomes, and we are steadfast in our collaboration, innovation and ambition to deliver

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
116 John St. Suite 300, Lowell, MA, 01852
Telephone
Telephone
(978) 709-1946
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/14/3188602/0/en/Biogen-Completes-Acquisition-of-Alcyone-Therapeutics.html

GLOBENEWSWIRE
15 Nov 2025

https://www.fiercebiotech.com/biotech/biogen-puts-its-back-85m-alcyone-buyout-securing-tech-spinal-drug-delivery

FIERCE BIOTECH
19 Sep 2025

https://www.prnewswire.com/news-releases/alcyone-therapeutics-announces-strategic-financing-to-advance-an-expanded-pipeline-of-pediatric-focused-precision-therapeutics-for-severe-neurological-diseases-302436946.html

PR NEWSWIRE
24 Apr 2025

https://www.prnewswire.com/news-releases/alcyone-therapeutics-announces-continued-enrollment-approval-from-fda-of-the-pierre-pivotal-ide-clinical-study-of-the-thecaflex-drx-system-for-administration-of-nusinersen-302210909.html

PR NEWSWIRE
31 Jul 2024

https://www.prnewswire.com/news-releases/alcyone-therapeutics-announces-appointment-of-dr-norbert-riedel-as-chairman-of-the-board-and-dr-kathrin-meyer-as-chief-scientific-officer-and-head-of-research--development-302139018.html

PR NEWSWIRE
08 May 2024

https://www.prnewswire.com/news-releases/alcyone-therapeutics-receives-fda-ide-approval-to-initiate-clinical-study-of-the-thecaflex-drxtm-system-for-administration-of-spinraza-nusinersen-301863840.html

PR NEWSWIRE
27 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty